Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168


Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice.

Qian J, Dong Y, Pang YY, Ibrahim R, Berzofsky JA, Schiller JT, Khleif SN.

Int J Cancer. 2006 Jun 15;118(12):3022-9.


Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.

Bellone S, El-Sahwi K, Cocco E, Casagrande F, Cargnelutti M, Palmieri M, Bignotti E, Romani C, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

J Virol. 2009 Jul;83(13):6779-89. doi: 10.1128/JVI.02443-08. Epub 2009 Apr 22.


HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination.

Kaufmann AM, Nieland J, Schinz M, Nonn M, Gabelsberger J, Meissner H, Müller RT, Jochmus I, Gissmann L, Schneider A, Dürst M.

Int J Cancer. 2001 Apr 15;92(2):285-93.


Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice.

Peng S, Trimble C, He L, Tsai YC, Lin CT, Boyd DA, Pardoll D, Hung CF, Wu TC.

Gene Ther. 2006 Jan;13(1):67-77.


Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine.

Chang EY, Chen CH, Ji H, Wang TL, Hung K, Lee BP, Huang AY, Kurman RJ, Pardoll DM, Wu T.

Int J Cancer. 2000 Jun 1;86(5):725-30.


Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model.

Greenstone HL, Nieland JD, de Visser KE, De Bruijn ML, Kirnbauer R, Roden RB, Lowy DR, Kast WM, Schiller JT.

Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1800-5.


Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice.

Liu XS, Abdul-Jabbar I, Qi YM, Frazer IH, Zhou J.

Virology. 1998 Dec 5;252(1):39-45.


Human papillomavirus type 16 E7 peptide-directed CD8+ T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein.

Nilges K, Höhn H, Pilch H, Neukirch C, Freitag K, Talbot PJ, Maeurer MJ.

J Virol. 2003 May;77(9):5464-74.


A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.

Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, Kast WM, Fascio G, Marty V, Weber J.

Clin Cancer Res. 2000 Sep;6(9):3406-16.


Immunogenicity of dendritic cell-based HPV16 E6/E7 peptide vaccines: CTL activation and protective effects.

Indrová M, Reinis M, Bubeník J, Jandlová T, Bieblová J, Vonka V, Velek J.

Folia Biol (Praha). 2004;50(6):184-93.


Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines.

Da Silva DM, Schiller JT, Kast WM.

Vaccine. 2003 Jul 4;21(23):3219-27.


Human papillomavirus type 16 E7 peptide(38-61) linked with an immunoglobulin G fragment provides protective immunity in mice.

Qin Y, Wang XH, Cui HL, Cheung YK, Hu MH, Zhu SG, Xie Y.

Gynecol Oncol. 2005 Feb;96(2):475-83.


A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers.

Riemer AB, Keskin DB, Zhang G, Handley M, Anderson KS, Brusic V, Reinhold B, Reinherz EL.

J Biol Chem. 2010 Sep 17;285(38):29608-22. doi: 10.1074/jbc.M110.126722. Epub 2010 Jul 8.


Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLA-A*0201-restricted T-cell peptides in cervical cancer patients.

Liu DW, Yang YC, Lin HF, Lin MF, Cheng YW, Chu CC, Tsao YP, Chen SL.

J Virol. 2007 Mar;81(6):2869-79. Epub 2007 Jan 3.


A novel self-assembled nanoparticle vaccine with HIV-1 Tat₄₉₋₅₇/HPV16 E7₄₉₋₅₇ fusion peptide and GM-CSF DNA elicits potent and prolonged CD8⁺ T cell-dependent anti-tumor immunity in mice.

Tang J, Yin R, Tian Y, Huang Z, Shi J, Fu X, Wang L, Wu Y, Hao F, Ni B.

Vaccine. 2012 Feb 1;30(6):1071-82. doi: 10.1016/j.vaccine.2011.12.029. Epub 2011 Dec 15.


Hsp70-like protein 1 fusion protein enhances induction of carcinoembryonic antigen-specific CD8+ CTL response by dendritic cell vaccine.

Wu Y, Wan T, Zhou X, Wang B, Yang F, Li N, Chen G, Dai S, Liu S, Zhang M, Cao X.

Cancer Res. 2005 Jun 1;65(11):4947-54.

Supplemental Content

Support Center